Focused On-demand Library for RNA cytidine acetyltransferase

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9H0A0

UPID:

NAT10_HUMAN

Alternative names:

18S rRNA cytosine acetyltransferase; N-acetyltransferase 10; N-acetyltransferase-like protein

Alternative UPACC:

Q9H0A0; B4DFD5; E7ESU4; E9PMN9; Q86WK5; Q9C0F4; Q9HA61; Q9NVF2

Background:

RNA cytidine acetyltransferase, known as N-acetyltransferase 10, plays a pivotal role in post-transcriptional modifications, catalyzing the formation of N(4)-acetylcytidine (ac4C) in mRNAs, 18S rRNA, and tRNAs. This modification enhances mRNA stability and translation efficiency, particularly within wobble cytidine sites. It is also involved in early nucleolar cleavages of precursor rRNA, essential for 18S rRNA synthesis, and acetylates lysine residues of various proteins, including histones and p53/TP53, albeit its in vivo relevance remains to be fully elucidated.

Therapeutic significance:

Understanding the role of RNA cytidine acetyltransferase could open doors to potential therapeutic strategies, especially considering its involvement in mRNA stability and protein acetylation, which are crucial processes in cellular function and disease progression.